Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.

被引：0
|
作者：
Chang, Kevin [1 ]
Lodha, Roshan [2 ]
Delavan, Henry M. [3 ]
Winebaum, Jenna [3 ]
Porten, Sima P. [1 ]
Feng, Felix Y. [3 ]
Chu, Carissa E. [1 ]
Chou, Jonathan
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Cleveland Clin, Lerner Coll Med, Cleveland Hts, OH USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
3282-646-2719; 613-615-646-4685-2424; 283-183-138-226-9326; 283-183-138-11076; 261-374-2500-10670-7136; 5; 3; 2; 3224; 1876; 1; 38092-33344; 38092-27054;
D O I：
10.1200/JCO.2024.42.4_suppl.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：690 / 690
页数：1
相关论文
共 50 条
  • [31] Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it
    Wang, Yuanyuan
    Chen, Jiyuan
    Wu, Zhengjie
    Ding, Weihong
    Gao, Shen
    Gao, Yuan
    Xu, Chuanliang
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (02) : 239 - 261
  • [32] Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance
    Aggen, David H.
    Chu, Carissa E.
    Rosenberg, Jonathan E.
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1377 - 1380
  • [33] Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome
    Pulingam, Thiruchelvi
    Parumasivam, Thaigarajan
    Mohd Gazzali, Amirah
    Mohd Sulaimana, Azlinah
    Chee, Jiun Yee
    Lakshmanan, Manoj
    Chin, Chai Fung
    Sudesh, Kumar
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 170
  • [34] Recent strategies to overcome breast cancer resistance
    Khan, Muhammad Muzamil
    Yalamarty, Satya Siva Kishan
    Rajmalani, Bharat Ashok
    Filipczak, Nina
    Torchilin, Vladimir P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 197
  • [35] Therapeutic strategies to overcome taxane resistance in cancer
    Das, Tuyelee
    Anand, Uttpal
    Pandey, Swaroop Kumar
    Ashby, Charles R., Jr.
    Assaraf, Yehuda G.
    Chen, Zhe-Sheng
    Dey, Abhijit
    DRUG RESISTANCE UPDATES, 2021, 55
  • [36] Enfortumab vedotin for cisplatin-ineligible urothelial cancer Comment
    Pignot, Geraldine
    LANCET ONCOLOGY, 2021, 22 (06): : 748 - 749
  • [37] Enfortumab vedotin - next game-changer in urothelial cancer
    Maas, Moritz
    Stuehler, Viktoria
    Walz, Simon
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 801 - 809
  • [38] Different strategies to overcome multidrug resistance in cancer
    Saraswathy, Manju
    Gong, Shaoqin
    BIOTECHNOLOGY ADVANCES, 2013, 31 (08) : 1397 - 1407
  • [39] Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
    Shi, Zhen-duo
    Hao, Lin
    Han, Xiao-xiao
    Wu, Zhuo-Xun
    Pang, Kun
    Dong, Yang
    Qin, Jia-xin
    Wang, Guang-yue
    Zhang, Xuan-ming
    Xia, Tian
    Liang, Qing
    Zhao, Yan
    Li, Rui
    Zhang, Shao-qi
    Zhang, Jun-hao
    Chen, Jian-gang
    Wang, Gong-cheng
    Chen, Zhe-Sheng
    Han, Cong-hui
    MOLECULAR CANCER, 2022, 21 (01)
  • [40] Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
    Zhen-duo Shi
    Lin Hao
    Xiao-xiao Han
    Zhuo-Xun Wu
    Kun Pang
    Yang Dong
    Jia-xin Qin
    Guang-yue Wang
    Xuan-ming Zhang
    Tian Xia
    Qing Liang
    Yan Zhao
    Rui Li
    Shao-qi Zhang
    Jun-hao Zhang
    Jian-gang Chen
    Gong-cheng Wang
    Zhe-Sheng Chen
    Cong-hui Han
    Molecular Cancer, 21
12345